Frontline advancement Insights from the 2025 Canadian Hypertension Guidelines

References

[1] Goupil R , Tsuyuki RT , Santesso N , et al. Hypertension Canada guideline for the diagnosis and treatment of hypertension in adults in primary care. CMAJ. 2025; 197: E549- 64.

[2] Nerenberg KA , Zarnke KB , Leung AA , et al. ; Hypertension Canada. Hypertension Canada. Hypertension Canada's 2018 Guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children. Can J Cardiol. 2018; 34: 506- 25.

[3] Qi Y , Han X , Zhao D , et al. Long-term cardiovascular risk associated with stage 1 hypertension defined by the 2017 ACC/AHA hypertension guideline. J Am Coll Cardiol. 2018; 72: 1201- 10.

[4] Liu S , Wang Y , Xie Y , et al. The association of stage 1 hypertension defined by the 2017 ACC/AHA hypertension guideline and subsequent cardiovascular events among adults <50 years. J Hum Hypertens. 2020; 34: 233- 40.

[5] Wu S , Xu Y , Zheng R , et al. Hypertension defined by 2017 ACC/AHA Guideline, ideal cardiovascular health metrics, and risk of cardiovascular disease: a nationwide prospective cohort study. Lancet Reg Health West Pac. 2022; 20: 100350.

[6] Liuxin LI , Chenrui Z , Liming L , et al. Impact of different blood pressure levels on the risk of early-onset stroke in young adults. Chin J Hypertension. 2022; 30: 1061- 8.

[7] Wang Z , Chen Z , Zhang L , et al.; China Hypertension Survey Investigators. Status of hypertension in China: results from the China hypertension survey, 2012-2015. Circulation. 2018; 137: 2344- 56.

[8] Wang Z , Hao G , Wang X , et al.; China hypertension survey investigators. Clinical outcomes and economic impact of the 2017 ACC/AHA Guidelines on hypertension in China. J Clin Hypertens (Greenwich). 2019; 21: 1212- 20.

[9] Ma S , Yang L , Zhao M , Magnussen CG , Xi B . Trends in hypertension prevalence, awareness, treatment and control rates among Chinese adults, 1991-2015. J Hypertens. 2021; 39: 740- 8.

[10] Brguljan-Hitij J , Thijs L , Li Y , et al.; International Database on Ambulatory Blood Pressure in Relation to Cardiovascular Outcome Investigators. Risk stratification by ambulatory blood pressure monitoring across JNC classes of conventional blood pressure. Am J Hypertens. 2014; 27: 956- 65.

[11] Vemu PL , Yang E , Ebinger JE . Moving Toward a Consensus: comparison of the 2023 ESH and 2017 ACC/AHA Hypertension Guidelines. JACC:Advances. JACC Adv. 2024; 3: 101230.

[12] McCarthy CP , Bruno RM , Brouwers S , et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024; 45: 3912- 4018.

[13] Whelton PK , Carey RM , Aronow WS , et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018; 71: e127- 248.

[14] Guo X , Sun G , Xu Y , et al.; BPRULE Study Group. Benefitharm trade-offs of intensive blood pressure control versus standard blood pressure control on cardiovascular and renal outcomes: an individual participant data analysis of randomised controlled trials. Lancet. 2025; 406: 1009- 19.

[15] SPRINT Research Group . A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015; 373: 2103- 16.

[16] Zhang W , Zhang S , Deng Y , et al. Trial of intensive bloodpressure control in older patients with hypertension. N Engl J Med. 2021; 385: 1268- 79.

[17] He J , Ouyang N , Guo X , et al.; CRHCP Study Group. Effectiveness of a non-physician community health-care provider-led intensive blood pressure intervention versus usual care on cardiovascular disease (CRHCP): an open-label, blinded-endpoint, clusterrandomised trial. Lancet (London, England). 2023; 401: 928- 38.

[18] Bi Y , Li M , Liu Y , et al. Intensive blood-pressure control in patients with type 2 diabetes. N Engl J Med. 2025; 392: 1155- 67.

[19] Zhang D , Lee JS , Pollack LM , et al. Association of Economic Policies With Hypertension Management and Control: a systematic review[C]//JAMA Health Forum. American Medical Association. JAMA Health Forum. 2024; 5: e235231- e235231.

[20] Jaffe MG , Young JD . The Kaiser Permanente Northern California Story:Improving hypertension control from 44% to 90% in 13 years (2000 to 2013). J Clin Hypertens (Greenwich). 2016; 18: 260- 1.

[21] Nolde JM , Beaney T , Carnagarin R , Schutte AE , Poulter NR , Schlaich MP . Global impact of different blood pressure thresholds in 4, 021, 690 participants of the May measurement month initiative. Hypertension. 2022; 79: 1497- 505.

[22] Li J , Zhao D , Cai J , et al. Cost-effectiveness of treatment in adults with blood pressure of 130-139/80-89 mmHg and high cardiovascular risk in China: a modelling study. Lancet Reg Health West Pac. 2024; 42: 100962.

[23] Wenjun S , Ziyin Z , Zheyu C , et al. A systematic review of the impact of centralized drug procurement policies on drug prices and usage. Chin J Health Policy. 2023; 16: 52- 8.

RIGHTS & PERMISSIONS

by the Authors, published by Wolters Kluwer Health, Inc. on behalf of Higher Education Press.